LGP2 overexpression decreases the transcript levels of the IFN signaling and proinflammatory cytokines during ZIKV infection. by Zhongyuan Tan (5779016)

RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. by Xiaojuan Li (351842)

Inhibition of the mitochondrial fission decreases mtROS production. by Dong Ma (584680)

Number of tdT+ cells in the cortex of <i>Nkx2.1</i>-cKO mice at E14.5. by Sathish Venkataramanappa (10331993)

Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome. by Jennifer Gribble (10005444)

RNF5 depletion decreases cellular gene expression and lytic replication through increased EphA3 and EphA4 level in iSLK.219 cells. by Xiaojuan Li (351842)

RNF5 depletion suppresses PEL xenograft tumor growth and decreases the levels of cell cycle gene expression and hedgehog signaling in tumors. by Xiaojuan Li (351842)

Inclusion of TPP side chains result in decreased melanoma cell mitochondria membrane potential, oxygen consumption, and increased DHE oxidation. by Kyle C. Kloepping (9928265)

“…(C) A375 melanoma cells were treated with 1.0 μM 5-, 8-, 10-, 12-,14-, or 16-TPP for 1.5 h and analyzed for DHE oxidation (* significant relative to control; p<0.05; n = 3 from 2 separate experiments; N = 6). …”

Figure 5 from TGFβ Inhibition during Radiotherapy Enhances Immune Cell Infiltration and Decreases Metastases in Ewing Sarcoma by Jessica D. Daley (22128489)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: